ClinicalTrials.gg
RecruitingNCT06968936Updated Apr 13, 2026

Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy

An interventional study of Sucrose Iron,subcutaneous recombinant human erythropoietin,intravenous vitamin C and Routine perioperative management in Anemia, Iron Deficiencies and Cardiac Surgery, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 116 studies in Anemia with a site in China — 32 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.

Planned enrollment
13th of 98
400 · median 120
Started
2026
with 4 others
No phase
20 of 116
5 open now
Primary completion
2029-06
later than 41 of 41 live
Registered
101st of 116
by date
Lead sponsor
5 of 116
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 116 studies in Anemia with a site in China, this one is the 13th largest by planned enrollment of the 98 interventional ones that give a count, is one of 5 that started in 2026, is one of 20 with no phase, reaches primary completion later than 41 of the 41 other live ones, and was the 101st registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

32 of the 116 studies in Anemia with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Anemia with a site in China, or all of them as a file.
02

Study summary

This is a sub-study of the Preoperative Combined Iron Therapy trail in which some participants will be additionally randomized to combined iron supplementation or standarded treatment control to evaluate the impact on long-term outcomes.

03

Conditions studied

  • Anemia
  • Iron Deficiencies
  • Cardiac Surgery
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be at least 18 years of age.
  2. Major cardiac surgery should encompass procedures such as coronary artery bypass grafting (CABG), valve surgery, or a combination of both.
  3. Iron deficiency anemia is defined as having a ferritin level below 100 μg/L or a ferritin level below 300 μg/L accompanied by a transferrin saturation below 25%. Additionally, levels should range between 90 and 130 g/L for men or between 90 and 120 g/L for women.
  4. The (ASA) classification should fall within Grade 1-3.
  5. Prior to participation, the patient or their legal representative must provide .

Exclusion criteria

Exclusion Criteria:

  1. for the administration of iron sucrose, ascorbic acid, or rHuEPO.
  2. Presence of a temperature exceeding 37.5 °C or the utilization of non-prophylactic antibiotics.
  3. Individuals with a weight equal to or less than 50kg.
  4. Individuals with a family history of haemochromatosis or thalassaemia, or those with a transferrin saturation level exceeding 50% or a documented history of iron overload.
  5. Presence of other known haematological disorders such as folic acid or vitamin B12 deficiency, haemolytic anaemia, haemoglobinopathies, iron granulocytic anaemia, G6PD deficiency, etc.
  6. Requirement for emergency surgical intervention.
  7. Severe hepatic or renal impairment, >3 times the value or AST >3 times the upper limit of normal value, creatinine >1.5 times the upper limit of normal value
  8. Pregnant or lactating women
  9. history of blood transfusion, intravenous iron or ascorbic acid use within 12 weeks prior to surgery
  10. Acute blood loss, gastrointestinal bleeding, etc. in the preoperative period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Combined Iron Supplementation Group

    Patients in the experimental group will receive a combination therapy consisting of intravenous sucrose iron (200 mg), subcutaneous recombinant human erythropoietin (150 IU/kg), and intravenous vitamin C (2 g), administered once daily for three consecutive days within the week prior to surgery. All perioperative transfusion decisions will follow standardized restrictive transfusion thresholds

    Drug: Sucrose Iron,subcutaneous recombinant human erythropoietin,intravenous vitamin C

  • Active comparator
    Conventional treatment group

    Routine perioperative management based on clinical judgment, including observation, monitoring, and standard nursing practices

    Procedure: Routine perioperative management

Interventions

  • DrugSucrose Iron,subcutaneous recombinant human erythropoietin,intravenous vitamin C

    Patients in the experimental group will receive a combination therapy consisting of intravenous sucrose iron (200 mg), subcutaneous recombinant human erythropoietin (150 IU/kg), and intravenous vitamin C (2 g), administered once daily for three consecutive days within the week prior to surgery.

    Also known as: Routine perioperative management

  • ProcedureRoutine perioperative management

    Routine perioperative management based on clinical judgment, including observation, monitoring, and standard nursing practices.

06

What researchers measure

Primary outcomes

  1. Quality of Life (EQ-5D)

    Assessment of health-related quality of life using the EuroQol 5-Dimension (EQ-5D) questionnaire

    Time frame: 1 year postoperatively (±30 days)

Secondary outcomes

  1. Sleep Quality (Pittsburgh Sleep Quality Index, PSQI)

    Evaluation of sleep quality using the Pittsburgh Sleep Quality Index (PSQI)

    Time frame: 1 year postoperatively (±30 days)

  2. Fatigue (FACIT-Fatigue Scale)

    Measurement of fatigue level using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale.

    Time frame: 1 year postoperatively (±30 days)

  3. All-cause Complications

    Occurrence of any postoperative complications from any cause during the 1-year follow-up period

    Time frame: Up to 1 year postoperatively

  4. Hospital Readmission

    Any hospital readmission for any cause within 1 year after surgery.

    Time frame: Up to 1 year postoperatively

  5. Repeat Cardiac Surgery

    Any subsequent cardiac surgery (reoperation) within 1 year after the index surgery.

    Time frame: Up to 1 year postoperatively

  6. All-cause Mortality

    Death from any cause within 1 year after surgery.

    Time frame: Up to 1 year postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zeroual N, Blin C, Saour M, David H, Aouinti S, Picot MC, Colson PH, Gaudard P. Restrictive Transfusion Strategy after Cardiac Surgery. Anesthesiology. 2021 Mar 1;134(3):370-380. doi: 10.1097/ALN.0000000000003682. PubMed 33475735 ↗
  • Fowler AJ, Ahmad T, Abbott TEF, Torrance HD, Wouters PF, De Hert S, Lobo SM, Rasmussen LS, Della Rocca G, Beattie WS, Wijeysundera DN, Pearse RM; International Surgical Outcomes Study Group. Association of preoperative anaemia with postoperative morbidity and mortality: an observational cohort study in low-, middle-, and high-income countries. Br J Anaesth. 2018 Dec;121(6):1227-1235. doi: 10.1016/j.bja.2018.08.026. Epub 2018 Oct 25. PubMed 30442249 ↗
  • Carson JL, Brittenham GM. How I treat anemia with red blood cell transfusion and iron. Blood. 2023 Aug 31;142(9):777-785. doi: 10.1182/blood.2022018521. PubMed 36315909 ↗
  • Spahn DR, Schoenrath F, Spahn GH, Seifert B, Stein P, Theusinger OM, Kaserer A, Hegemann I, Hofmann A, Maisano F, Falk V. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. Lancet. 2019 Jun 1;393(10187):2201-2212. doi: 10.1016/S0140-6736(18)32555-8. Epub 2019 Apr 26. PubMed 31036337 ↗
  • Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 2006 Apr;47(4):644-54. doi: 10.1053/j.ajkd.2005.12.025. PubMed 16564942 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2029, 39 months after the start.

Of 165 non-industry interventional studies with no phase under Anemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's planned 39 months is above that.

Counting every sponsor, half of 179 studies reached it within 17 months; a quarter within 7 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2025
First posted
May 13, 2025
StartActual
Mar 27, 2026
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06968936
Collaborators
First Affiliated Hospital of Chongqing Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Wenzhou Medical University, Zhejiang Provincial People's Hospital
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Mar 27, 2026
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Apr 13, 2026

Study contacts

Qi Gao, Dr.
Contact
gaoqi19950203@163.com
19857136919

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion